Evidence map›Paper›PMID 38491559›Full record

Trial reportAddiction science & clinical practice2024

Feasibility of precision smoking treatment in a low-income community setting: results of a pilot randomized controlled trial in The Southern Community Cohort Study.

Scott S Lee, Nicole Senft Everson, Maureen Sanderson, Rebecca Selove, William J Blot, Stephen King, Karen Gilliam, Suman Kundu, Mark Steinwandel, Sarah J Sternlieb and 12 more

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Addiction science & clinical practice, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03521141 (Developing Precision Smoking Treatment in the Southern Community Cohort Study), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03521141 phase2 / phase3completednot on this map

Developing Precision Smoking Treatment in the Southern Community Cohort Study

TypeinterventionalSponsorVanderbilt University Medical CenterRan2018 to 2019Enrolled67ConditionsTobacco Use CessationArmsNicotine patch, Varenicline, Nicotine metabolism, Genetically-informed lung cancer risk score, NCI "Clearing the Air"
3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 7 institutions in 3 countries.

Scott S Lee *Vanderbilt University Medical Center, 2525 West End Ave. Suite 450, Nashville, TN, 37203, USA. s.s.lee@vanderbilt.edu.ORCID http://orcid.org/0000-0002-0970-1941
Nicole Senft Everson *Vanderbilt University Medical Center, 2525 West End Ave. Suite 450, Nashville, TN, 37203, USA.
Maureen SandersonMeharry Medical College, Nashville, TN, USA.
Rebecca SeloveTennessee State University, Nashville, TN, USA.
William J BlotVanderbilt University Medical Center, 2525 West End Ave. Suite 450, Nashville, TN, 37203, USA.
Stephen KingVanderbilt University Medical Center, 2525 West End Ave. Suite 450, Nashville, TN, 37203, USA.
Karen GilliamVanderbilt University Medical Center, 2525 West End Ave. Suite 450, Nashville, TN, 37203, USA.
Suman KunduVanderbilt University Medical Center, 2525 West End Ave. Suite 450, Nashville, TN, 37203, USA.
Mark SteinwandelVanderbilt University Medical Center, 2525 West End Ave. Suite 450, Nashville, TN, 37203, USA.
Sarah J SternliebVanderbilt University Medical Center, 2525 West End Ave. Suite 450, Nashville, TN, 37203, USA.
Qiuyin CaiVanderbilt University Medical Center, 2525 West End Ave. Suite 450, Nashville, TN, 37203, USA.
Shaneda Warren AndersenVanderbilt University Medical Center, 2525 West End Ave. Suite 450, Nashville, TN, 37203, USA.
Debra L FriedmanVanderbilt University Medical Center, 2525 West End Ave. Suite 450, Nashville, TN, 37203, USA.
Erin Connors KellyVanderbilt University Medical Center, 2525 West End Ave. Suite 450, Nashville, TN, 37203, USA.
Mary Kay FaddenMeharry Medical College, Nashville, TN, USA.
Matthew S FreibergVanderbilt University Medical Center, 2525 West End Ave. Suite 450, Nashville, TN, 37203, USA.
Quinn S WellsVanderbilt University Medical Center, 2525 West End Ave. Suite 450, Nashville, TN, 37203, USA.
Juan CanedoMeharry Medical College, Nashville, TN, USA.
Rachel F TyndaleCentre for Addiction and Mental Health, and Departments of Pharmacology & Toxicology, and Psychiatry, Campbell Family Mental Health Research Institute, University of Toronto, Toronto, ON, Canada.
Robert P YoungUniversity of Auckland, Auckland, New Zealand.
Raewyn J HopkinsUniversity of Auckland, Auckland, New Zealand.
Hilary A TindleVanderbilt University Medical Center, 2525 West End Ave. Suite 450, Nashville, TN, 37203, USA.
Vanderbilt University Medical Center · USMeharry Medical College · USGeriatric Research Education and Clinical Center · USUniversity of Auckland · NZCentre for Addiction and Mental Health · CATennessee State University · USUniversity of Wisconsin–Madison · US

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Ben Ho Park · 1995 to 2026
$172.8M
Vanderbilt Institute for Clinical and Translational Research (VICTR) -Identifying correlates of functional immunity in SARS-CoV-2 convalescent plasmaUL1TR002243 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Paul A. Harris, Wesley H Self · 2017 to 2026
$130.7M
TrainingU54CA163072 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Karen Marie Winkfield · 2011 to 2026
$20.1M
Translational Pathology CoreU54CA163069 · NCI · MEHARRY MEDICAL COLLEGE · PI ADUNYAH, SAMUEL EVANS, STEWART, LAMONICA VANETTE · 2011 to 2025
$18.8M
TRAININGU54CA163066 · NCI · TENNESSEE STATE UNIVERSITY · PI MARGARET M WHALEN · 2011 to 2026
$12.8M
Learning Health System training program: PROgRESS--Patient/ pRactice Outcomes and Research in Effectiveness and Systems ScienceT32HS026122 · AHRQ · VANDERBILT UNIVERSITY MEDICAL CENTER · PI GRIJALVA, CARLOS G, ROUMIE, CHRISTIANNE L. · 2018 to 2024
$3.5M
Vanderbilt Scholars in T4 Translational Research (V-STTaR) ProgramK12HL137943 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI KRIPALANI, SUNIL, ROUMIE, CHRISTIANNE L. · 2017 to 2021
$2.9M
Measuring and modifying delay discounting as a mechanism of smoking in pregnancyK08DA058046 · NIDA · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Scott Lee · 2024 to 2026
$555k
AHRQ HHS T32 HS026122NCATS NIH HHS UL1 TR002243NCATS NIH HHS UL1TR002243NCI NIH HHS P30 CA068485NCI NIH HHS U54 CA163066NCI NIH HHS U54CA163066NCI NIH HHS U54 CA163069NCI NIH HHS U54CA163069NCI NIH HHS U54 CA163072NCI NIH HHS U54CA163072-09S1NHLBI NIH HHS K12 HL137943NHLBI NIH HHS K12HL137943NIDA NIH HHS K08 DA058046
6 · The paper itself

Abstract

backgroundThe feasibility of precision smoking treatment in socioeconomically disadvantaged communities has not been studied.

methodsParticipants in the Southern Community Cohort Study who smoked daily were invited to join a pilot randomized controlled trial of three smoking cessation interventions: guideline-based care (GBC), GBC plus nicotine metabolism-informed care (MIC), and GBC plus counseling guided by a polygenic risk score (PRS) for lung cancer. Feasibility was assessed by rates of study enrollment, engagement, and retention, targeting > 70% for each. Using logistic regression, we also assessed whether feasibility varied by age, sex, race, income, education, and attitudes toward precision smoking treatment.

resultsOf 92 eligible individuals (79.3% Black; 68.2% with household income < $15,000), 67 (72.8%; 95% CI 63.0-80.9%) enrolled and were randomized. Of these, 58 (86.6%; 95% CI 76.4-92.8%) engaged with the intervention, and of these engaged participants, 43 (74.1%; 95% CI 61.6-83.7%) were retained at 6-month follow-up. Conditional on enrollment, older age was associated with lower engagement (OR 0.83, 95% CI 0.73-0.95, p = 0.008). Conditional on engagement, retention was significantly lower in the PRS arm than in the GBC arm (OR 0.18, 95% CI 0.03-1.00, p = 0.050). No other selection effects were observed.

conclusionsGenetically informed precision smoking cessation interventions are feasible in socioeconomically disadvantaged communities, exhibiting high enrollment, engagement, and retention irrespective of race, sex, income, education, or attitudes toward precision smoking treatment. Future smoking cessation interventions in this population should take steps to engage older people and to sustain participation in interventions that include genetic risk counseling.

trial registrationClinicalTrials.gov No. NCT03521141, Registered 27 April 2018, https://www. CLINICALTRIALS: gov/study/NCT03521141.

Indexed as

SmokingTobacco SmokingAgedCohort StudiesFeasibility StudiesFemaleHumansMalePilot ProjectsHealth disparitiesPrecision medicineSmoking cessation treatment

Identifiers

PMID38491559
PMCPMC10941447
OpenAlexW4392853360

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.